Delivering a trading update this morning, the
It also expects its core operating margin to reach the top end of its previous guidance range off 22 per cent to 24 per cent, driven by a “more favourable product mix”, which now includes over 120 products, 14 of which were launched this year.
In
The business also continues to expect global injectables revenue to grow in the mid-single digits and core operating margin to be in the range of 37 per cent to 38 per cent.
“We have made excellent progress year to date, including launching new specialty products, establishing new partnerships and using our robust balance sheet to expand our portfolio and pipeline,” said
“While the global pandemic continues to bring some volatility, we are leveraging our resilient commercial and operational capabilities to drive growth and to reliably deliver medicines to our customers and patients.”
The post
© City AM, source